Immuno oncology product for multiple myeloma: g-NK cellular therapy to optimize monoclonal antibody efficacy in treating multiple
Ended Cooperative Agreement Awarded Last action
- Award ID
- R43CA235786
- Recipient
-
Indapta Therapeutics Inc. UEI FW7PJD4KQXC7
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $300,000
Award facts
- Assistance listing
- 93.395 Cancer Treatment Research
- Completion date
- Place of performance
- San Diego, CA 92127, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Original award | $300,000 |
Quick answers
Who received award R43CA235786?
R43CA235786 was awarded to Indapta Therapeutics Inc. by National Cancer Institute (National Institutes of Health) on May 15, 2019.
How much is award R43CA235786 worth?
$300,000 has been obligated on R43CA235786.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award